Moataz Hamed Osman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Moataz Hamed Osman has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Samir Alfaar
Affiliation Department of Ophthalmology, Charité Universitätsmedizin Berlin, Berlin, Germany
2 shared publications Ahmed M Abdelrahman
Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Dokki, Egypt
1 shared publicationAmira F.Z. El Hewehi
Department of Ophthalmology, Cairo University Hospital, Cairo, Egypt
1 shared publicationAmr Abdellatif Osman
Faculty of Medicine, Cairo University, Giza, Egypt
1 shared publication- Anas M. Saad
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio USA
1 shared publication Dalia Mohammed Fawzy Mohamed
Department of Ophthalmology, National Institute of Diabetes, Cairo, Egypt
1 shared publication
Latest Publications
- 11 September 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (11) , 2375-2386
Longitudinal nationwide analysis of uveal melanoma in the United States 1995–2018
Purpose Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, yet comprehensive nationwide epidemiologic data remain limited. This study aimed to provide an updated analysis of UM incidence, survival, and disparities in the United States (US) using near-complete population coverage. Methods We analyzed data from the North American Association of Central Cancer Registries (NAACCR) and US Cancer Statistics (USCS) program between 1995 and 2018, covering 98–100% of the US population. Age-adjusted incidence rates (AAIRs) and relative survival were calculated using SEER*Stat and Joinpoint regression. Results A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48–5.59), showing a stable but slightly increasing trend (AAPC = 0.06). Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75–79 years. Geographic variation was notable, with peak incidence in Oregon and Iowa. Most tumors (81.3%) were localized at diagnosis, and 27.4% of patients had another primary malignancy. 5- and 10-year relative survival rates were 83.3% and 73.9%, respectively, with worse outcomes in metastatic disease. A shift toward radiotherapy, especially brachytherapy, was observed, although survival gains remained limited. Conclusions This nationwide study refines US UM incidence estimates and highlights persistent disparities by sex, race, age, and geography. The high prevalence of secondary malignancies underscores the need for genetic counseling and extended surveillance. Despite advances in imaging, local therapies (e.g., brachytherapy, proton therapy), and emerging systemic approaches including immunotherapy, survival improvements in advanced UM remain limited.
- 11 September 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (11) , 2375-2386
Longitudinal nationwide analysis of uveal melanoma in the United States 1995–2018
Purpose Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, yet comprehensive nationwide epidemiologic data remain limited. This study aimed to provide an updated analysis of UM incidence, survival, and disparities in the United States (US) using near-complete population coverage. Methods We analyzed data from the North American Association of Central Cancer Registries (NAACCR) and US Cancer Statistics (USCS) program between 1995 and 2018, covering 98–100% of the US population. Age-adjusted incidence rates (AAIRs) and relative survival were calculated using SEER*Stat and Joinpoint regression. Results A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48–5.59), showing a stable but slightly increasing trend (AAPC = 0.06). Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75–79 years. Geographic variation was notable, with peak incidence in Oregon and Iowa. Most tumors (81.3%) were localized at diagnosis, and 27.4% of patients had another primary malignancy. 5- and 10-year relative survival rates were 83.3% and 73.9%, respectively, with worse outcomes in metastatic disease. A shift toward radiotherapy, especially brachytherapy, was observed, although survival gains remained limited. Conclusions This nationwide study refines US UM incidence estimates and highlights persistent disparities by sex, race, age, and geography. The high prevalence of secondary malignancies underscores the need for genetic counseling and extended surveillance. Despite advances in imaging, local therapies (e.g., brachytherapy, proton therapy), and emerging systemic approaches including immunotherapy, survival improvements in advanced UM remain limited.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Delta Journal of Ophthalmology
- Vol. 26 (2) , 103-110
Efficacy and safety of intracameral betamethasone versus dexamethasone at the end of phacoemulsification
Purpose: The current study aimed to determine the safety and efficacy of intracameral injection of betamethasone or dexamethasone at the end of phacoemulsification in decreasing postoperative inflammation. Patients and methods: This is a comparative, prospective, interventional, randomized study that was carried out at Cairo University Hospital, Cairo, Egypt. It included 90 patients with age-related cataracts for whom phacoemulsification was performed. They were randomized into three equal groups: the betamethasone group had an intracameral injection of 0.2 mg/0.1 ml betamethasone at the surgery end, the dexamethasone group received an intracameral injection of 0.4 mg/0.1 ml dexamethasone at the surgery end, and the control group who did not receive either drug. All patients were evaluated for anterior chamber inflammation (cells and flare), LogMAR best-corrected visual acuity, corneal endothelial cell count, pachymetry, and intraocular pressure (IOP) 14 days after surgery. Results: On the 14th postoperative day, all patients of the betamethasone and dexamethasone groups had grade 0 cells and flare, while in the control group, 20% had grade 1 cells and 16.6% grade 1 flare, with a statistically significant difference (betamethasone vs. control: P=0.02 and dexamethasone vs. control: P=0.02). The mean LogMAR best-corrected visual acuity was 0.4±0.2, 0.3±0.1, and 0.5±0.2 in the betamethasone, dexamethasone, and control groups, respectively (betamethasone vs. control: P=0.005 and dexamethasone vs. control: P=0.003). The mean endothelial cell count was 2160.2±336.3, 2185.3±381.7, and 1892.3±352.3 cells/mm2, respectively (betamethasone vs. control: P=0.005 and dexamethasone vs. control: P=0.002). The mean corneal pachymetry was 563.9±37.1, 565.4±26.9, and 585.5±26.4 μm, respectively (betamethasone vs. control: P=0.03 and dexamethasone vs. control: P=0.01). According to the post-hoc analysis, the betamethasone versus the dexamethasone groups exhibited no significant differences. The mean IOP was 12.8±1.1, 12.2±1.07, and 13.0±1.7 mmHg, respectively, without significant difference (P=0.06). Conclusion: At the end of uneventful phacoemulsification, intracameral dexamethasone or betamethasone significantly minimized the postoperative ocular inflammation and corneal endothelial cell loss and did not increase the IOP. Thus, injecting either intracameral dexamethasone or betamethasone at the end of cataract surgery is recommended.
- 1 April 2025
- Published by Wolters Kluwer Health in Delta Journal of Ophthalmology
- Vol. 26 (2) , 103-110
Open AccessEfficacy and safety of intracameral betamethasone versus dexamethasone at the end of phacoemulsification
Purpose: The current study aimed to determine the safety and efficacy of intracameral injection of betamethasone or dexamethasone at the end of phacoemulsification in decreasing postoperative inflammation. Patients and methods: This is a comparative, prospective, interventional, randomized study that was carried out at Cairo University Hospital, Cairo, Egypt. It included 90 patients with age-related cataracts for whom phacoemulsification was performed. They were randomized into three equal groups: the betamethasone group had an intracameral injection of 0.2 mg/0.1 ml betamethasone at the surgery end, the dexamethasone group received an intracameral injection of 0.4 mg/0.1 ml dexamethasone at the surgery end, and the control group who did not receive either drug. All patients were evaluated for anterior chamber inflammation (cells and flare), LogMAR best-corrected visual acuity, corneal endothelial cell count, pachymetry, and intraocular pressure (IOP) 14 days after surgery. Results: On the 14th postoperative day, all patients of the betamethasone and dexamethasone groups had grade 0 cells and flare, while in the control group, 20% had grade 1 cells and 16.6% grade 1 flare, with a statistically significant difference (betamethasone vs. control: P=0.02 and dexamethasone vs. control: P=0.02). The mean LogMAR best-corrected visual acuity was 0.4±0.2, 0.3±0.1, and 0.5±0.2 in the betamethasone, dexamethasone, and control groups, respectively (betamethasone vs. control: P=0.005 and dexamethasone vs. control: P=0.003). The mean endothelial cell count was 2160.2±336.3, 2185.3±381.7, and 1892.3±352.3 cells/mm2, respectively (betamethasone vs. control: P=0.005 and dexamethasone vs. control: P=0.002). The mean corneal pachymetry was 563.9±37.1, 565.4±26.9, and 585.5±26.4 μm, respectively (betamethasone vs. control: P=0.03 and dexamethasone vs. control: P=0.01). According to the post-hoc analysis, the betamethasone versus the dexamethasone groups exhibited no significant differences. The mean IOP was 12.8±1.1, 12.2±1.07, and 13.0±1.7 mmHg, respectively, without significant difference (P=0.06). Conclusion: At the end of uneventful phacoemulsification, intracameral dexamethasone or betamethasone significantly minimized the postoperative ocular inflammation and corneal endothelial cell loss and did not increase the IOP. Thus, injecting either intracameral dexamethasone or betamethasone at the end of cataract surgery is recommended.
- Open Access
- 1 September 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (2) , 515-526
Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body
Purpose: The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body. Methods: We have queried the Surveillance, Epidemiology and End-Results “SEER”-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups. Results: Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere. Conclusions: The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin’s lymphoma and melanoma as first primary.
- 1 September 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (2) , 515-526
Open AccessSecond primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body
Purpose: The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body. Methods: We have queried the Surveillance, Epidemiology and End-Results “SEER”-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups. Results: Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere. Conclusions: The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin’s lymphoma and melanoma as first primary.
- 12 July 2019
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 28 (10) , 871-877
Role of Pattern Electroretinogram in Ocular Hypertension and Early Glaucoma
Purpose: To test whether pattern electroretinogram (PERG) can early detect retinal ganglion cells dysfunction in ocular hypertension. Design: Cross-sectional observational study. Participants: The study included 3 groups: control, primary open-angle glaucoma (POAG) and ocular hypertension (OHT) groups with 30 eyes in each group. Materials and Methods: Visual fields were examined using automated perimetry with central 24-2 program. Optical coherent tomography (OCT) was done to assess the neuroretinal rim area, vertical cup/disc ratio, and average superior and inferior retinal nerve fiber layer thickness. PERG was recorded using skin electrodes. Amplitude and latency of P50 and N95 were documented. Results: PERG data: the mean P50 and N95 latency were significantly higher in the POAG group and the OHT group compared with the control group (PPr=−0.620, P=0.001) and N95 amplitude (r=−0.61, Pr=0.51, P=0.007) and N95 amplitudes (r=0.50, P=0.002). However, there was no significant correlation between PERG parameters and OCT parameters. In the OHT group, PERG parameters did not correlate with visual field and OCT parameters. Conclusions: PERG can detect the dysfunctional, but still live retinal ganglion cells earlier than OCT in OHT cases, allowing the early start of treatment that can restore the ganglion cell function before irreversible damage occurs.
- 12 July 2019
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 28 (10) , 871-877
Role of Pattern Electroretinogram in Ocular Hypertension and Early Glaucoma
Purpose: To test whether pattern electroretinogram (PERG) can early detect retinal ganglion cells dysfunction in ocular hypertension. Design: Cross-sectional observational study. Participants: The study included 3 groups: control, primary open-angle glaucoma (POAG) and ocular hypertension (OHT) groups with 30 eyes in each group. Materials and Methods: Visual fields were examined using automated perimetry with central 24-2 program. Optical coherent tomography (OCT) was done to assess the neuroretinal rim area, vertical cup/disc ratio, and average superior and inferior retinal nerve fiber layer thickness. PERG was recorded using skin electrodes. Amplitude and latency of P50 and N95 were documented. Results: PERG data: the mean P50 and N95 latency were significantly higher in the POAG group and the OHT group compared with the control group (PPr=−0.620, P=0.001) and N95 amplitude (r=−0.61, Pr=0.51, P=0.007) and N95 amplitudes (r=0.50, P=0.002). However, there was no significant correlation between PERG parameters and OCT parameters. In the OHT group, PERG parameters did not correlate with visual field and OCT parameters. Conclusions: PERG can detect the dysfunctional, but still live retinal ganglion cells earlier than OCT in OHT cases, allowing the early start of treatment that can restore the ganglion cell function before irreversible damage occurs.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 13, 921-925
Subfoveal choroidal thickness in diabetic macular edema
Purpose: To evaluate subfoveal choroidal thickness (SFCT) in eyes with diabetic macular edema (DME) using spectral domain OCT (SD-OCT). Materials and methods: Ninety eyes were divided into three equal groups: group A, non-proliferative diabetic retinopathy (NPDR) with no DME; group B, NPDR having DME; and group C, non-diabetic patients. The central subfield retinal thickness (CSRT) and SFCT were measured using spectral domain OCT. Results: There was a moderate negative correlation between age and SFCT in group B (r=−0.455, P=0.012). We found no significant correlation between best corrected visual acuity (BCVA) and SFCT in all groups (for groups A, B, and C, respectively: r=0.189, P=0.316; r=−0.195, P=0.302; and r=−0.181, P=0.337). There was no significant correlation between duration of diabetes and SFCT (r=−0.118, P=0.534 and r=−0.136, P=0.475 for groups A and B, respectively). The CSRT was 229.13±16.2, 336.4±74.85, and 223.13±16.9 μm in groups A, B, and C, respectively. The mean SFCT was 260.6±49.2, 259±50.8, and 252±50 μm in groups A, B, and C, respectively. We found no significant correlation between CSRT and SFCT in all groups (for groups A, B, and C, respectively: r=−0.049, P=0.796, r=0.239, P=0.204, r=−0.021, P=0.914). There was no significant difference in SFCT between group B (DME) on one hand and groups A and C on the other hand (P=0.9 and 0.59, respectively). Conclusion: There is no significant correlation between CSRT and SFCT in DME. Choroidal thickness assessment is not an indicator of the severity of DME and cannot be used as a monitor of its progression.
- 1 May 2019
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 13, 921-925
Open AccessSubfoveal choroidal thickness in diabetic macular edema
Purpose: To evaluate subfoveal choroidal thickness (SFCT) in eyes with diabetic macular edema (DME) using spectral domain OCT (SD-OCT). Materials and methods: Ninety eyes were divided into three equal groups: group A, non-proliferative diabetic retinopathy (NPDR) with no DME; group B, NPDR having DME; and group C, non-diabetic patients. The central subfield retinal thickness (CSRT) and SFCT were measured using spectral domain OCT. Results: There was a moderate negative correlation between age and SFCT in group B (r=−0.455, P=0.012). We found no significant correlation between best corrected visual acuity (BCVA) and SFCT in all groups (for groups A, B, and C, respectively: r=0.189, P=0.316; r=−0.195, P=0.302; and r=−0.181, P=0.337). There was no significant correlation between duration of diabetes and SFCT (r=−0.118, P=0.534 and r=−0.136, P=0.475 for groups A and B, respectively). The CSRT was 229.13±16.2, 336.4±74.85, and 223.13±16.9 μm in groups A, B, and C, respectively. The mean SFCT was 260.6±49.2, 259±50.8, and 252±50 μm in groups A, B, and C, respectively. We found no significant correlation between CSRT and SFCT in all groups (for groups A, B, and C, respectively: r=−0.049, P=0.796, r=0.239, P=0.204, r=−0.021, P=0.914). There was no significant difference in SFCT between group B (DME) on one hand and groups A and C on the other hand (P=0.9 and 0.59, respectively). Conclusion: There is no significant correlation between CSRT and SFCT in DME. Choroidal thickness assessment is not an indicator of the severity of DME and cannot be used as a monitor of its progression.
- 6 September 2018
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 29 (4) , 453-457
Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes
Purpose: To compare the efficacy of addition of nonsteroidal anti-inflammatory eye drops to steroidal eye drops with that of using postoperative steroidal anti-inflammatory eye drops alone in prevention of macular edema in high-risk patients.Setting: Cairo University Hospital.Design: This study was comparative prospective interventional randomized study.Methods: This study included 100 cataractous eyes divided into five subgroups: 20 eyes of diabetic patients, 20 uveitic eyes, 20 traumatic cataracts, 20 glaucomatous eyes on topical prostaglandin analogs, and 20 eyes with posterior capsular rupture during phacoemulsification. Each subgroup of 20 was randomized between two groups of 10 eyes, group A received postoperative topical steroids alone and group B received both steroidal and nonsteroidal anti-inflammatory eye drops.Results: There was significant increase in postoperative central foveal thickness as compared to preoperative values in both groups (60.9 ± 87.95 µ in group A and 25.52 ± 57.26 µ in group B) that was significantly more in group A (P value 0.016). There was significant difference in postoperative macular thickness between both groups (280.1 ± 86.0 µ and 246.80 ± 57.73 µ, respectively, in groups A and B) (P value = 0.012). There was no statistically significant difference between both groups in preoperative and postoperative corrected distance visual acuity and intraocular pressure.Conclusion: Addition of topical nepafenac eye drops to topical steroid drops significantly reduced the amount of pseudophakic macular edema after cataract surgery in high-risk eyes.
- 6 September 2018
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 29 (4) , 453-457
Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes
Purpose: To compare the efficacy of addition of nonsteroidal anti-inflammatory eye drops to steroidal eye drops with that of using postoperative steroidal anti-inflammatory eye drops alone in prevention of macular edema in high-risk patients.Setting: Cairo University Hospital.Design: This study was comparative prospective interventional randomized study.Methods: This study included 100 cataractous eyes divided into five subgroups: 20 eyes of diabetic patients, 20 uveitic eyes, 20 traumatic cataracts, 20 glaucomatous eyes on topical prostaglandin analogs, and 20 eyes with posterior capsular rupture during phacoemulsification. Each subgroup of 20 was randomized between two groups of 10 eyes, group A received postoperative topical steroids alone and group B received both steroidal and nonsteroidal anti-inflammatory eye drops.Results: There was significant increase in postoperative central foveal thickness as compared to preoperative values in both groups (60.9 ± 87.95 µ in group A and 25.52 ± 57.26 µ in group B) that was significantly more in group A (P value 0.016). There was significant difference in postoperative macular thickness between both groups (280.1 ± 86.0 µ and 246.80 ± 57.73 µ, respectively, in groups A and B) (P value = 0.012). There was no statistically significant difference between both groups in preoperative and postoperative corrected distance visual acuity and intraocular pressure.Conclusion: Addition of topical nepafenac eye drops to topical steroid drops significantly reduced the amount of pseudophakic macular edema after cataract surgery in high-risk eyes.
- 13 July 2017
- Published by Wolters Kluwer Health in Cornea
- Vol. 36 (9) , 1036-1039
Incidence of Posterior Vitreous Detachment After Femtosecond LASIK Compared With Microkeratome LASIK
Purpose: To compare the incidence of posterior vitreous detachment (PVD) after femtosecond and microkeratome laser in situ keratomileusis (LASIK). Setting: Rowad Correction Centre, Cairo, Egypt (a private center affiliated to Cairo University). Design: Prospective, nonrandomized comparative unmasked study. Methods: The study was conducted at a single laser center. Eligible patients chose between femtosecond and microkeratome LASIK after appropriate counseling. B-scan ultrasonography was performed before surgery by a single operator. Patients with preexisting PVD (partial or complete) were excluded. The axial length was also recorded. All surgery was performed by a single surgeon. During surgery, the suction time was measured. Ultrasonography was repeated 1 month after surgery by the same operator to detect PVD. Results: Ten patients (20 eyes, group M) underwent LASIK using the Moria M2 microkeratome, and 10 patients (20 eyes, group F) underwent femtosecond LASIK with the IntraLase FS-150. In groups M and F, respectively, the proportion of women was 80% and 70%, and the mean age was 24.7 ± 4 years and 25.7 ± 3.3 years, the mean axial length was 24.2 ± 1.2 and 23.8 ± 1.2 mm, and the mean suction time was 18 ± 2 seconds and 63 ± 4 seconds (P < 0.001). After surgery, PVD was detected in 4 eyes (20%) in group M and 17 eyes (85%) in group F (P = 0.000044). Conclusions: The incidence of PVD 1 month after femtosecond LASIK was higher than after microkeratome LASIK. This may be due to longer suction time during femtosecond LASIK despite lower suction pressure.
- 13 July 2017
- Published by Wolters Kluwer Health in Cornea
- Vol. 36 (9) , 1036-1039
Incidence of Posterior Vitreous Detachment After Femtosecond LASIK Compared With Microkeratome LASIK
Purpose: To compare the incidence of posterior vitreous detachment (PVD) after femtosecond and microkeratome laser in situ keratomileusis (LASIK). Setting: Rowad Correction Centre, Cairo, Egypt (a private center affiliated to Cairo University). Design: Prospective, nonrandomized comparative unmasked study. Methods: The study was conducted at a single laser center. Eligible patients chose between femtosecond and microkeratome LASIK after appropriate counseling. B-scan ultrasonography was performed before surgery by a single operator. Patients with preexisting PVD (partial or complete) were excluded. The axial length was also recorded. All surgery was performed by a single surgeon. During surgery, the suction time was measured. Ultrasonography was repeated 1 month after surgery by the same operator to detect PVD. Results: Ten patients (20 eyes, group M) underwent LASIK using the Moria M2 microkeratome, and 10 patients (20 eyes, group F) underwent femtosecond LASIK with the IntraLase FS-150. In groups M and F, respectively, the proportion of women was 80% and 70%, and the mean age was 24.7 ± 4 years and 25.7 ± 3.3 years, the mean axial length was 24.2 ± 1.2 and 23.8 ± 1.2 mm, and the mean suction time was 18 ± 2 seconds and 63 ± 4 seconds (P < 0.001). After surgery, PVD was detected in 4 eyes (20%) in group M and 17 eyes (85%) in group F (P = 0.000044). Conclusions: The incidence of PVD 1 month after femtosecond LASIK was higher than after microkeratome LASIK. This may be due to longer suction time during femtosecond LASIK despite lower suction pressure.
- 1 January 2017
- Published by Medknow in Delta Journal of Ophthalmology
- Vol. 18 (2) , 94
‘Wipe-out’ after subscleral trabeculectomy in advanced glaucoma patients
Purpose The aim of this study was to evaluate the safety of trabeculectomy in advanced glaucoma patients in the Egyptian population, and to detect postoperative wipe-out syndrome in high-risk patients. Patients and methods Thirty-six eyes of 33 patients with advanced glaucoma were included in the study. All patients underwent subscleral trabeculectomy. The patients were followed up for 3 months during which intraocular pressure (IOP), best-corrected visual acuity (BCVA), slit lamp biomicroscopy, fundus examination, and perimetry were done. Results The mean age of the study group was 51.17±2.64 years. The study included 24 males and nine females. The mean preoperative BCVA was 0.36±0.33. the mean IOP was 31±8.75 mmHg and the mean number of medications was 3.08±0.1. In all cases, complete success was achieved except for two cases with qualified success. The BCVA at day 90 showed no change in 21 eyes, visual decline in three eyes and visual gain in 12 eyes. A negative linear correlation was noticed between the percent reduction in IOP and the reduction in BCVA in the first postoperative day (r=−0.239) which was not statistically significant (P=0.162). The color of the neuroretinal rim was not a significant determinant for the final BCVA (P=0.48). Visual field changes showed no statistically significant differences. Conclusion Wipe-out phenomenon is not an ultimate postoperative outcome for filtering surgery in patients with advanced glaucoma. Pale neuroretinal rim and postoperative hypotony are risk factors for postoperative visual deterioration.
- 1 January 2017
- Published by Medknow in Delta Journal of Ophthalmology
- Vol. 18 (2) , 94
‘Wipe-out’ after subscleral trabeculectomy in advanced glaucoma patients
Purpose The aim of this study was to evaluate the safety of trabeculectomy in advanced glaucoma patients in the Egyptian population, and to detect postoperative wipe-out syndrome in high-risk patients. Patients and methods Thirty-six eyes of 33 patients with advanced glaucoma were included in the study. All patients underwent subscleral trabeculectomy. The patients were followed up for 3 months during which intraocular pressure (IOP), best-corrected visual acuity (BCVA), slit lamp biomicroscopy, fundus examination, and perimetry were done. Results The mean age of the study group was 51.17±2.64 years. The study included 24 males and nine females. The mean preoperative BCVA was 0.36±0.33. the mean IOP was 31±8.75 mmHg and the mean number of medications was 3.08±0.1. In all cases, complete success was achieved except for two cases with qualified success. The BCVA at day 90 showed no change in 21 eyes, visual decline in three eyes and visual gain in 12 eyes. A negative linear correlation was noticed between the percent reduction in IOP and the reduction in BCVA in the first postoperative day (r=−0.239) which was not statistically significant (P=0.162). The color of the neuroretinal rim was not a significant determinant for the final BCVA (P=0.48). Visual field changes showed no statistically significant differences. Conclusion Wipe-out phenomenon is not an ultimate postoperative outcome for filtering surgery in patients with advanced glaucoma. Pale neuroretinal rim and postoperative hypotony are risk factors for postoperative visual deterioration.